IL-3 Rat anti-Mouse, Clone: DNAX MP28F8-1, Invitrogen
Rat Monoclonal Antibody
Manufacturer: Invitrogen MA523797
In Western blots, no cross-reactivity with recombit human (rh) IL-3 or recombit rat IL-3 is observed. This antibody does not neutralize the biological activity of rhIL-3. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.Interleukin 3 (IL-3), also called Mast Cell Growth Factor (MCGF), Multi-Colony Stimulating Factor (multi-CSF), or Eosinophil-CSF (E-CSF), is produced by activated T cells, mast cells and eosinophils. IL-3 is a hematopoietic growth factor that stimulates colony formation of erythroid, megakaryocyte, neutrophil, eosinophil, basophil, mast cell and monocytic lineages. Most of these functions are enhanced or dependent on co-stimulation with other cytokines. Human and mouse IL-3 share only 29% sequence identity at the amino acid level. The bioactivity of IL-3 is highly species specific. For example, human IL-3 has no activity on mouse cells. IL-3 is a potent growth promoting cytokine. IL-3 is capable of supporting the proliferation of a broad range of hematopoietic cell types, and is involved in a variety of cell activities such as cell growth, differentiation and apoptosis. IL-3 has been shown to also possess neurotrophic activity, and it may be associated with neurologic disorders.
|PBS with 5% trehalose and No Preservative|
|Interleukin-3, IL3, Multipotential colony-stimulating factor, Hematopoietic growth factor, P-cell-stimulating factor, Mast-cell growth factor, MCGF|
|-20° C, Avoid Freeze/Thaw Cycles|
|ELISA, Neutralization, Western Blot|
|COS-7 African green monkey SV40 transformed kidney fibroblast-like cell line-derived recombit mouse IL-3|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok